RESUMEN
Pancreatic ß cells are responsible for insulin secretion and are important for glucose regulation in a healthy body and diabetic disease patient without prelabeling of islets. While the conventional biomarkers for diabetes have been glucose and insulin concentrations in the blood, the direct determination of the pancreatic ß cell mass would provide critical information for the disease status and progression. By combining fluorination and diversity-oriented fluorescence library strategy, we have developed a multimodal pancreatic ß cell probe PiF for both fluorescence and for PET (positron emission tomography). By simple tail vein injection, PiF stains pancreatic ß cells specifically and allows intraoperative fluorescent imaging of pancreatic islets. PiF-injected pancreatic tissue even facilitated an antibody-free islet analysis within 2 h, dramatically accelerating the day-long histological procedure without any fixing and dehydration step. Not only islets in the pancreas but also the low background of PiF in the liver allowed us to monitor the intraportal transplanted islets, which is the first in vivo visualization of transplanted human islets without a prelabeling of the islets. Finally, we could replace the built-in fluorine atom in PiF with radioactive 18F and successfully demonstrate in situ PET imaging for pancreatic islets.
Asunto(s)
Colorantes Fluorescentes/química , Células Secretoras de Insulina/citología , Xantenos/química , Animales , Diabetes Mellitus Experimental/patología , Fluorescencia , Colorantes Fluorescentes/síntesis química , Colorantes Fluorescentes/farmacocinética , Colorantes Fluorescentes/toxicidad , Humanos , Células Secretoras de Insulina/trasplante , Trasplante de Islotes Pancreáticos , Hígado/citología , Ratones Endogámicos C57BL , Ratones Endogámicos ICR , Tomografía de Emisión de Positrones , Ratas , Xantenos/síntesis química , Xantenos/farmacocinética , Xantenos/toxicidadRESUMEN
Islet cell transplantation is a promising option for the restoration of normal glucose homeostasis in patients with type 1 diabetes. Because graft volume is a crucial issue in islet transplantations for patients with diabetes, we evaluated a new method for increasing functional tissue yield in xenogeneic grafts of encapsulated islets. Islets were labeled with three different superparamagnetic iron oxide nano particles (SPIONs; dextran-coated SPION, siloxane-coated SPION, and heparin-coated SPION). Magnetic separation was performed to separate encapsulated islets from the empty capsules, and cell viability and function were tested. Islets labeled with 1000 µg Fe/ml dextran-coated SPIONs experienced a 69.9% reduction in graft volume, with a 33.2% loss of islet-containing capsules. Islets labeled with 100 µg Fe/ml heparin-coated SPIONs showed a 46.4% reduction in graft volume, with a 4.5% loss of capsules containing islets. No purification could be achieved using siloxane-coated SPIONs due to its toxicity to the primary islets. SPION labeling of islets is useful for transplant purification during islet separation as well as in vivo imaging after transplantation. Furthermore, purification of encapsulated islets can also reduce the volume of the encapsulated islets without impairing their function by removing empty capsules.
Asunto(s)
Separación Celular/métodos , Compuestos Férricos , Trasplante de Islotes Pancreáticos/métodos , Islotes Pancreáticos/citología , Magnetismo , Nanopartículas , Trasplante Heterólogo/métodos , Animales , Recuento de Células , Supervivencia Celular/fisiología , Dextranos , Heparina , Humanos , Islotes Pancreáticos/fisiología , Imagen por Resonancia Magnética , Ratas , Ratas Wistar , SiloxanosRESUMEN
Pancreatic islet transplantation is a promising strategy for the treatment of type I diabetes. High-mobility group box-1 (HMGB1), highly expressed in islet cells, is a potent immune stimulator in immune rejection. Heme oxygenase-1 (HO1) gene therapy can modulate the release of HMGB1 by altering intracellular molecules for successful cell transplantation. After delivery of the heme oxygenase-1 (HO1) gene to islet cells using an adeno-associated viral vector (AAV), it was evaluated the changes in cytoplasmic Ca2+ ions and calcineurin activity as well as histone acetyltransferase (HAT) and Poly(ADP) ribose polymerase-1 (PARP-1). Inhibition of HMGB1 release was evaluated through altering these intracellular molecules. Then, after transplantation of HO1-transduced islets, the therapeutic effect of them was evaluated through measuring blood glucose level to diabetic mice and through immunohistochemical analysis. The transduced HO1 gene significantly inhibited HMGB1 release in islets that was under the cell damage by hypoxia exposure. It was confirmed that this result was initially due to the decrease in cytoplasmic Ca2+ ion concentration and calcineurin activity. In addition, the delivered HO1 gene simultaneously reduced the activity of HAT and PARP-1, which are involved in the translocation of HMGB1 from the nucleus to the cytoplasm. As a result, when the HO1 gene-transduced islets were transplanted into diabetic mice, the treatment efficiency of diabetes was effectively improved by increasing the survival rate of the islets. Collectively, these results suggest that HO1 gene transfer can be used for successful islet transplantation by altering the activity of intracellular signal molecules and reducing HMGB1 release.
Asunto(s)
Diabetes Mellitus Experimental , Proteína HMGB1 , Trasplante de Islotes Pancreáticos , Islotes Pancreáticos , Animales , Calcineurina/metabolismo , Calcineurina/farmacología , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/terapia , Proteína HMGB1/genética , Hemo-Oxigenasa 1/genética , Hemo-Oxigenasa 1/metabolismo , Hemo-Oxigenasa 1/farmacología , Trasplante de Islotes Pancreáticos/métodos , Ratones , Inhibidores de Poli(ADP-Ribosa) PolimerasasRESUMEN
BACKGROUND: Superparamagnetic iron oxide (SPIO) nanoparticles have been widely used in several biomedical engineering in vivo. Although various surface modifications have been made to these non-biodegradable nanoparticles to make them more biocompatible, their toxic potential still remains a major concern. METHOD: In this study, we newly developed unfractionated heparin (UFH)-coated and low molecular weight heparin (LMWH)-coated SPIO nanoparticles through surface modification engineering, which was compared with commercially available dextran-coated SPIO nanoparticles. Their toxicity such as cytotoxicity, single cell gel electrophoresis (SCGE) comet assay, intracellular reactive oxygen species (ROS) content and cellular apoptosis was evaluated to hepatic HepG2 and renal HK-2 cells. RESULTS: When UFH-, LMWH- or dextran-coated SPIO nanoparticles were applied, they did not affect the viability of HepG2 cell. However, HK-2 cells were more sensitive to dextran-coated SPIO nanoparticles than others. In genotoxicity assay using SCGE comet, DNA tail moment values in the groups treated with dextran- and LMWH-coated SPIO nanoparticles significantly increased. However, UFH-coated SPIO nanoparticles was only significantly lowing DNA tail moment value. In addition, UFH-coated SPIO nanoparticles had lower cytotoxicity in HepG2 and HK-2 cells compared to dextran-coated SPIO nanoparticles, especially in terms of apoptosis and intracellular ROS production. CONCLUSIONS: Collectively, it is possible that UFH- coated SPIO nanoparticles can be used as alternative negative contrast agents.
RESUMEN
Intermittent subcutaneous (S.C.) injection of teriparatide [PTH (1-34)] is one of the effective therapies to cure osteoporosis. However, a long-term repeated administration of teriparatide by S.C. to the patients is highly challenging. Herein, a triple padlock nanocarrier prepared by a taurocholic acid-conjugated chondroitin sulfate A (TCSA) is designed to develop an oral dosage form of recombinant human teriparatide (rhPTH). Oral administration of TCSA/rhPTH to the bilateral ovariectomized (OVX) rats resulted in the recovery of the bone marrow density and healthy serum bone parameters from the severe osteoporotic conditions. Also, it enhanced new bone formation in the osteoporotic tibias. This triple padlock oral delivery platform overcame the current barriers associated with teriparatide administration and exhibited a promising therapeutic effect against osteoporosis.
Asunto(s)
Portadores de Fármacos , Circulación Enterohepática/fisiología , Nanopartículas , Osteoporosis/metabolismo , Teriparatido , Administración Oral , Animales , Huesos/efectos de los fármacos , Huesos/fisiología , Sulfatos de Condroitina/química , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/química , Portadores de Fármacos/farmacocinética , Femenino , Humanos , Ratones , Ratones Endogámicos ICR , Nanopartículas/administración & dosificación , Nanopartículas/química , Nanopartículas/metabolismo , Osteoblastos/efectos de los fármacos , Ovariectomía , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacocinética , Ácido Taurocólico/química , Teriparatido/administración & dosificación , Teriparatido/farmacocinética , Teriparatido/farmacologíaRESUMEN
Type 2 diabetes mellitus (T2DM) is a chronic and progressive hyperglycemic condition. Glucagon-like peptide-1 (GLP1) is an incretin secreted from pancreatic ß-cells and helps to produce insulin to balance the blood glucose level without the risk of hypoglycemia. However, the therapeutic application of GLP1 is limited by its intrinsic short half-life and rapid metabolic clearance in the body. To enhance the antidiabetic effect of GLP1, we designed a human cysteine-modified IgG1-Fc antibody-mediated oral gene delivery vehicle, which helps to produce GLP1 sustainably in the target site with the help of increased half-life of the Fc-conjugated nanocarrier, protects GLP1 from acidic and enzymatic degradation in the gastrointestinal (GI) tract, uptakes and transports the GLP1 formulation through the neonatal Fc receptor (FcRn), and helps to release the GLP1 gene in the intestine. Our formulation could reduce the blood glucose from about an average of 320 mg/dL (hyperglycemic) to 150 mg/dL (normal blood glucose concentration) in diabetic mice, which is about 50% reduction of the total blood glucose concentration. GLP1 (500 µg) complexed with the IgG1-Fc carrier was proven to be the optimal dose for a complete reduction of hyperglycemic conditions in diabetic mice. A significant amount of insulin production and the presence of GLP1 peptide were observed in the pancreatic islets of oral GLP1 formulation-treated diabetic mice in immunohistochemistry analysis compared to nontreated diabetic mice. The orally given formulation was completely nontoxic according to the histopathology analysis of mice organ tissues, and no mice death was observed. Our antibody-mediated oral gene delivery system is a promising tool for various oral therapeutic gene delivery applications to treat diseases like diabetes.
Asunto(s)
Técnicas de Transferencia de Gen , Péptido 1 Similar al Glucagón/genética , Nanoestructuras/química , Receptores Fc/química , Administración Oral , Animales , Glucemia/análisis , Supervivencia Celular/efectos de los fármacos , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Experimental/terapia , Portadores de Fármacos/química , Portadores de Fármacos/toxicidad , Inmunoglobulina G/química , Intestino Delgado/metabolismo , Ratones , Protaminas/química , Rodaminas/química , Succinimidas/química , Distribución Tisular , TranscitosisRESUMEN
Various types of particle-based drug delivery systems have been explored for the treatment of pulmonary diseases; however, bio-distribution and elimination of the particles should be monitored for better understanding of their therapeutic efficacy and safety. This study aimed to characterize the biological properties of micro-sized discoidal polymeric particles (DPPs) as lung-targeted drug delivery carriers. DPPs were prepared using a top-down fabrication approach and characterized by assessing size and zeta potential. They were labeled with zirconium-89 (89Zr), and bio-distribution studies and PET imaging were performed for 7 days after intravenous administration. Their hydrodynamic size was 2.8⯱â¯6.1⯵m and average zeta potential was -39.9⯱â¯5.39â¯mV. At doses of 5, 12.5, and 25â¯mg/kg, they showed no acute toxicity in nude mice. Desferrioxamine (DFO)-functionalized 89Zr-labeled DPPs gave a decay-corrected radiochemical yield of 82.1⯱â¯0.2%. Furthermore, 89Zr-DPPs, from chelate-free labeling methods, showed a yield of 48.5⯱â¯0.9%. Bio-distribution studies and PET imaging showed 89Zr-DFO-DPPs to be mainly accumulated in the lungs and degraded within 3â¯d of injection. However, 89Zr-DFO-DPPs showed significantly low uptake in the bone. Overall, our results suggested micro-sized DPPs as promising drug delivery carriers for the targeted treatment of various pulmonary diseases.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Polímeros/química , Animales , Deferoxamina/química , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , Enfermedades Pulmonares/tratamiento farmacológico , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Tomografía de Emisión de Positrones/métodos , Radioisótopos/química , Temperatura , Circonio/químicaRESUMEN
Pancreatic islet implantation in the liver is a promising approach for diabetes therapy. However, 70% of the islet mass fails to be engrafted in the liver due to the instant blood-mediated inflammatory reactions (IBMIR) resulting from direct contact between islet cells and the bloodstream. To overcome this issue, direct monitoring is very important for establishing prognosis after islet cell therapy. Here we established a new type of MR contrast agent with anticoagulant activity via heparin-immobilized superparamagnetic iron oxide (HSPIO). The HSPIO was chemically conjugated onto islet surface ex vivo without damage of their viability and functionality. The conjugated HSPIO nanoparticles onto islet surface could attenuate IBMIR in vitro and in vivo. The HSPIO-conjugated islets could cure the blood glucose levels of diabetes animals after implantation. In addition, the HSPIO nanoparticles were well maintained on the transplanted islets for a long time during modulation of inflammation. Also, they allowed for stable visualization of the implanted islet cells for more than 150 days without reduction of the MRI signal. Furthermore, when HSPIO itself was intraportally injected, it was rapidly eliminated without accumulation in the liver, suggesting that HSPIO nanoparticles could only track the immobilized islet. Collectively, this HSPIO nanoparticle having MRI sensitivity and anticoagulant activity could be utilized for successful islet implantation.
Asunto(s)
Anticoagulantes/administración & dosificación , Medios de Contraste/administración & dosificación , Diabetes Mellitus Experimental/cirugía , Trasplante de Islotes Pancreáticos , Islotes Pancreáticos/diagnóstico por imagen , Hígado/cirugía , Monitoreo Fisiológico/métodos , Animales , Glucemia/análisis , Compuestos Férricos/química , Heparina/sangre , Heparina/química , Humanos , Inflamación/diagnóstico , Inflamación/etiología , Inflamación/prevención & control , Imagen por Resonancia Magnética , Nanopartículas de Magnetita/química , Masculino , Ratones , Ratones Desnudos , Pronóstico , Ratas , Ratas Sprague-Dawley , Factores de TiempoRESUMEN
Pancreatic islet transplantation is a promising treatment for treatment of type 1 diabetes; however, transplantation outcomes have been disappointing due to early graft loss that is mediated by many immune responses. Immune cells not only directly damaged islet but also produced reactive oxygen species (ROS), which is highly toxic to islet cells. Metallothionein (MT) can provide protection against oxidative stress by scavenging various ranges of ROS including superoxide, hydroxyl radical, hydrogen peroxide and nitric oxide. For scavenging immune response-induced ROS, cell-penetrating Tat peptide-metallothionein (Tat-MT) was delivered into islets. The viability of Tat-MT-treated islets was not damaged during co-culture with macrophages or ROS-generating paraquat. When Tat-MT-treated islets were xenotransplanted, ROS production was significantly attenuated at the islets. Eventually, the survival time of Tat-MT-treated islets was significantly enhanced without any immunosuppressant medicine. Additionally, we confirmed that the survival time of Tat-MT-treated islets in all animals was dramatically improved when accompanied with low dose immunosuppressive agents (tacrolimus and anti-CD154 monoclonal antibody), indicating that Tat-MT delivery could have synergistic effect with immunosuppressants. Collectively, this new combination therapy of Tat-MT delivery with low dose immunosuppressant would be a powerful remedy for successful outcome of islet xenotransplantation.
Asunto(s)
Péptidos de Penetración Celular/metabolismo , Productos del Gen tat/metabolismo , Inmunomodulación , Trasplante de Islotes Pancreáticos , Metalotioneína/metabolismo , Trasplante Heterólogo , Animales , Técnicas de Cocultivo , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/cirugía , Productos del Gen tat/química , Insulina/metabolismo , Secreción de Insulina , Islotes Pancreáticos/inmunología , Islotes Pancreáticos/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismoRESUMEN
Although pancreatic islet implantation is an attractive strategy for curing diabetes mellitus, implanted cells are immunologically eliminated due to early islet graft loss. One of main issues in early islet graft loss is the secretion of high-mobility group-box-1 (HMGB1) protein from the damaged islet cells, which is known as a cytokine-like factor. Therefore, regulating the activity of HMGB1 protein offers an alternative strategy for improving outcomes of islet cell therapy. To this end, we first demonstrated that HMGB1 protein could be bound to its A-box fragment (HMGB1 A-box) with higher binding affinity, resembling anti-HMGB1 antibody. To be used as a pharmaceutical protein ex vivo, TAT-labeled HMGB1 A-box-His6 (TAT-HMGB1A) was structurally modified for cellular membrane penetration. TAT-HMGB1A significantly reduced secretion of endogenous HMGB1 protein through interaction in the cytosol without any damage to the viability or functionality of the islets. When TAT-HMGB1A-treated islets were implanted into diabetic nude mice, they completely cured diabetes, as evidenced by stable blood glucose level. TAT-HMGB1A treatment could also reduce the marginal islet mass needed to cure diabetes. Furthermore, TAT-HMGB1A positively protected xenotransplanted islets from xenogeneic immune reactions. Collectively, cell-penetrable TAT-HMGB1A could be used to modulate HMGB1 activity to increase successful outcomes of ex vivo pancreatic islet cell therapy.
Asunto(s)
Diabetes Mellitus Experimental/terapia , Proteína HMGB1/uso terapéutico , Trasplante de Islotes Pancreáticos/métodos , Islotes Pancreáticos/metabolismo , Animales , Diabetes Mellitus Experimental/metabolismo , Células HEK293 , Proteína HMGB1/administración & dosificación , Proteína HMGB1/química , Proteína HMGB1/metabolismo , Humanos , Islotes Pancreáticos/ultraestructura , Masculino , Ratones Desnudos , Ratas Sprague-DawleyRESUMEN
Graphene oxide (GO) has received increasing attention in bioengineering fields due to its unique biophysical and electrical properties, along with excellent biocompatibility. The application of GO nanoparticles (GO-NPs) to engineer self-renewal and differentiation of human fetal neural stem cells (hfNSCs) is reported. GO-NPs added to hfNSC culture during neurosphere formation substantially promote cell-to-cell and cell-to-matrix interactions in neurospheres. Accordingly, GO-NP-treated hfNSCs show enhanced self-renewal ability and accelerated differentiation compared to untreated cells, indicating the utility of GO in developing stem cell therapies for neurogenesis.
Asunto(s)
Feto/metabolismo , Grafito , Nanopartículas/química , Células-Madre Neurales/metabolismo , Neurogénesis/efectos de los fármacos , Esferoides Celulares/metabolismo , Feto/citología , Grafito/química , Grafito/farmacología , Humanos , Células-Madre Neurales/citología , Esferoides Celulares/citologíaRESUMEN
The number of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly basis. Current anti-diabetic medications often result in adverse weight gain and hypoglycemic episodes. Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which are expensive and require daily injections that may result immune activation. This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of bile acids. Oral administration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model. This novel oral GLP1 delivery system is an attractive alternative to treat late-stage T2DM conditions that require repeated insulin injection and can potentially minimize the occurrence of hypoglycemic anomalies.
Asunto(s)
ADN/administración & dosificación , Diabetes Mellitus Tipo 2/terapia , Técnicas de Transferencia de Gen , Péptido 1 Similar al Glucagón/genética , Animales , Línea Celular , ADN/química , Dieta Alta en Grasa , Femenino , Terapia Genética , Heparina/administración & dosificación , Heparina/química , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratas Sprague-Dawley , Ratas Zucker , Ácido Taurocólico/administración & dosificación , Ácido Taurocólico/químicaRESUMEN
Cynomolgus monkeys as nonhuman primates are valuable animal models because they have a high level of human gene homology. There are many reference values for hematology and biochemistry of Cynomolgus monkeys that are needed for proper clinical diagnosis and biomedical research conduct. The body weight information and blood type are also key success factors in allogeneic or xenogeneic models. Moreover, the biological parameters could be different according to the origin of the Cynomolgus monkey. However, there are limited references provided, especially of Cambodia origin. In this study, we measured average body weight of 2,518 Cynomolgus monkeys and analyzed hematology and serum biochemistry using 119 males, and determined blood types in 642 monkeys with Cambodia origin. The average body weight of male Cynomolgus monkeys were 2.56±0.345 kg and female group was 2.43±0.330 kg at the age from 2 to 3 years. The male group showed relatively sharp increased average body weight from the 3 to 4 age period compared to the female group. In hematology and biochemistry, it was found that most of the data was similar when compared to other references even though some results showed differences. The ABO blood type result showed that type A, B, AB, and O was approximately 15.6, 33.3, 44.2, and 6.9%, respectively. The main blood type in this facility was B and AB. These biological background references of Cambodia origin could be used to provide important information to researchers who are using them in their biomedical research.
RESUMEN
BACKGROUND: Pancreatic islet encapsulation is one way to address the disadvantages of islet transplantation. Not only does encapsulation involve bidirectional diffusion of nutrients, oxygen, and glucose, but also it protects the graft from the recipient's immune reaction. The high mobility group box 1 (HMGB1), one of higher expression proteins in islet, can be secreted from transplanted islets and induce the inflammation. Therefore, the regulation of HMGB1-mediated inflammation is very important for successful islet transplantation. In this study, we used the HMGB1 A box, an antagonist of HMGB1 receptor in the immune cells, in the encapsulation of isolated islets as a new strategy. RESULT: For co-encapsulation of HMGB1 A box protein with islets, we evaluated the distribution of alginate bead diameter. The average diameter of empty alginate bead was similar to that of alginate bead with islets. When different concentrations of HMGB1 A box protein was co-encapsulated with islets, it did not affect the viability and insulin secretion function of the islets. When the alginate beads with islets plus HMGB1 A box protein were cultured with macrophage, the amount of TNF-α secreted from the macrophages was significantly attenuated when compared to cultivation of unencapsulated islets or encapsulated islets. When the alginate beads with islets plus HMGB1 A box protein were intraperitoneally xenotransplanted into the diabetic mice, the survival rate of the islets was strongly improved with 2-fold. CONCLUSION: Collectively, these results suggested that the encapsulation of HMGB1 A box protein might offer a protective effect in islet transplantation.
RESUMEN
An approach is presented to create arrays of quasi-spherical microdroplets by surfaces called "spheroform" inspired by micro-/nanostructures found in the back of the Namib desert beetle. Spheroform is fabricated by microarray formation of catecholamine polymers on the superhydrophobic background. Spheroform is able to precisely control spheroid sizes of therapeutic islet cells and mesenchymal stem cells. The therapeutic spheroids exhibit improved biochemical activities.
Asunto(s)
Materiales Biomiméticos/uso terapéutico , Escarabajos/anatomía & histología , Nanoestructuras/uso terapéutico , Esferoides Celulares/citología , Animales , Humanos , Islotes Pancreáticos/citología , Células Madre Mesenquimatosas/citología , Propiedades de SuperficieRESUMEN
There is a clinical need for an alternative labeling agent for magnetic resonance imaging (MRI) in islet transplantation. We aimed to evaluate the feasibility of islet MRI using ferumoxytol, which is the only clinically-available ultrasmall superparamagnetic iron oxide. We compared islet function and viability of control islets and islets labeled with ferumoxytol and/or a heparin-protamine complex (HPF). Efficacy of ferumoxytol labeling was assessed in both ex vivo and in vivo models. Labeling for 48 h with HPF, but not up to 800 µg/mL ferumoxytol, deranged ex vivo islet viability and function. The T2∗ relaxation time was optimal when islets were labeled with 800 µg/mL of ferumoxytol for 48 h. Prussian blue stain, iron content assay, transmission electron microscopy (TEM) supported internalization of ferumoxytol particles. However, the labeling intensity in the ex vivo MRI of islets labeled with ferumoxytol was much weaker than that of islets labeled with ferucarbotran. In syngeneic intraportal islet transplantation, there was a correlation between the total area of visualized islets and the transplanted islet mass. In conclusion, islet MRI using ferumoxytol was feasible in terms of in vitro and in vivo efficacy and safety. However, the weak labeling efficacy is still a hurdle for the clinical application.
Asunto(s)
Óxido Ferrosoférrico/química , Trasplante de Islotes Pancreáticos , Islotes Pancreáticos/patología , Imagen por Resonancia Magnética , Animales , Supervivencia Celular , Medios de Contraste/química , Compuestos Férricos/química , Ferrocianuros/química , Heparina/química , Hierro/química , Magnetismo , Masculino , Nanopartículas del Metal/química , Ratones , Ratones Endogámicos C57BL , Microscopía Confocal , Microscopía Electrónica de Transmisión , Protaminas/química , Trasplante IsogénicoRESUMEN
Pancreatic islet transplantation is a promising method for treatment of type 1 diabetes mellitus. However, transplanted islets can be destroyed due to host immune reactions. To immunologically protect transplanted islets, here an immunoprotective microfiber including islets by using a polydimethylsiloxane (PDMS)-based microfluidic device is newly designed. A cylindrical-flow channel in the microfluidic platform is used for producing collagen-alginate composite (CAC) fibers. This enables mass production and uniform diameter distribution (<250 µm) without protruding islets. Collagen, which is the main extracellular matrix component, is added to alginate to mimic the native islet microenvironment. Compared to free islets (control) and alginate-fiber-encapsulated islets, CAC-fiber-encapsulated islets show higher viability and normal insulin secretion. When CAC-fiber-encapsulated islets (1200 islet equivalent) are implanted into the intraperitoneal cavity of streptozotocin-induced diabetic BALB/C mice, the blood glucose levels of all mice return to normoglycemia. Moreover, intraperitoneal glucose tolerance tests demonstrate that islets in the CAC-fiber have similar glucose responsiveness to those of non-diabetic normal mice. These results are attributed to the immunoprotection of the transplanted islets from host immune reactions. On the other hand, all free islets are completely rejected within a week due to severe immune responses. Collectively, fabrication of CAC fibers using microfluidic devices can be used for successful islet transplantation.
Asunto(s)
Trasplante de Islotes Pancreáticos/métodos , Islotes Pancreáticos/inmunología , Microfluídica/métodos , Animales , Supervivencia Celular/fisiología , Células Cultivadas , Ratones , Ratones Endogámicos BALB C , Microscopía Electrónica de Rastreo , Ratas Sprague-DawleyRESUMEN
Subcutaneous site is ideal for clinical islet transplantation because it has the advantage of simple operation procedure under local anesthesia and can be biopsied when needed. However, the transplantation outcomes at subcutaneous site have been disappointing due to hypoxia-induced oxidative stress by poor vascularization. We hypothesized that subcutaneously transplanted islets would have hypoxia resistance by using internalization of metallothionein (MT), an antioxidant scavenging enzyme, which was mediated by fusion between MT and cell penetrating Tat peptide. The Tat-MT was dose-dependently transduced into islets without any damage. Tat-MT-treated islets could be protected from oxidative stress induced by intracellular nitric oxide donor, sodium nitroprusside (SNP). When Tat-MT-treated islets were subcutaneously transplanted into diabetic nude mice, they normally controlled the blood glucose levels without severe fluctuation (median survival time (MST): >30 days), whereas most untreated islets were rejected (MST 17 days). From the intraperitoneal glucose tolerance test 5 days after posttransplantation, glucose responsiveness of Tat-MT-treated islets was similar to that of normal healthy mice, while untreated islets had delayed glucose responsiveness. From the results of immunohistochemical stain, Tat-MT-treated islets had strong anti-insulin positive cells and lower anti-HIF-1α positive cells. However, untreated islets had rare anti-insulin positive cells and strong anti-HIF-1α-positive cells. Collectively, these findings demonstrated that Tat-MT delivery into islet could offer a new strategy for successful islet transplantation under subcutaneous space.
Asunto(s)
Antioxidantes/uso terapéutico , Productos del Gen tat/uso terapéutico , Hipoxia/prevención & control , Trasplante de Islotes Pancreáticos/métodos , Metalotioneína/uso terapéutico , Secuencia de Aminoácidos , Animales , Antioxidantes/administración & dosificación , Antioxidantes/química , Productos del Gen tat/administración & dosificación , Productos del Gen tat/química , Glucosa/metabolismo , Prueba de Tolerancia a la Glucosa , Humanos , Hipoxia/metabolismo , Insulina/metabolismo , Islotes Pancreáticos/metabolismo , Masculino , Metalotioneína/administración & dosificación , Metalotioneína/química , Ratones , Datos de Secuencia Molecular , Estrés Oxidativo , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/uso terapéuticoRESUMEN
While subcutaneous tissue has been proposed as a potential site for pancreatic islet transplantation, concern remains that the microvasculature of subcutaneous tissue is too poor to support transplanted islets. In an effort to overcome this limitation, we evaluated whether fibrin gel with human adipose-derived stem cells (hADSCs) and rat pancreatic islets could cure diabetes mellitus when transplanted into the subcutaneous space of diabetic mice. Subcutaneously co-transplanted islets and hADSCs showed normalization of the diabetic recipient's blood glucose levels. The result was enhanced by co-treatment of fibroblast growth factor-2 (FGF2) in the fibrin gel. The hADSCs enhanced islet viability after transplantation by secreting various growth factors that can protect islets from hypoxic damage. Afterward, hADSCs could maintain islet viability by recruiting new microvasculature nearby the transplanted islets via overexpression of vascular endothelial growth factor (VEGF). The hADSCs did not directly differentiate into endothelial cells (no detection of biomarkers of human endothelial cells), but showed evidence of differentiation toward insulin-secreting cells (detection of human insulin). Mice receiving islet transplantation alone did not become normoglycemic. Collectively, co-transplantation of fibrin gel with islets and hADSCs will expand the indications for islet transplant therapy and the potential clinical application of cell-based therapy.
Asunto(s)
Tejido Adiposo/citología , Fibrina/farmacología , Trasplante de Islotes Pancreáticos , Islotes Pancreáticos/efectos de los fármacos , Trasplante de Células Madre , Tejido Subcutáneo/efectos de los fármacos , Animales , Biomarcadores/metabolismo , Técnicas de Cocultivo , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Experimental/terapia , Factor 2 de Crecimiento de Fibroblastos/farmacología , Geles , Humanos , Islotes Pancreáticos/irrigación sanguínea , Ratones , Microvasos/efectos de los fármacos , Microvasos/crecimiento & desarrollo , Neovascularización Fisiológica/efectos de los fármacos , Ratas , Ratas Endogámicas Lew , Supervivencia Tisular/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/metabolismoRESUMEN
Magnetic resonance imaging (MRI) is a tremendous modality for noninvasive cell tracking. To this end, superparamagnetic iron oxide (SPIO), one of the MRI contrast agents, should be labeled to the cells before transplantation. Currently, cellular labelling with SPIOs such as Feridex and Resovist is generally carried out through their engulfment into cytosol via endocytosis. However, the labelling efficacy via endocytosis is relatively low due to their non-specific random engulfment and degradation in the cytosol. To overcome these limitations, transfection agents such as poly-L-lysine and lipofectamine are complexed with SPIOs and treated to the cells. However, these strategies should be optimized due to the cytotoxicity of transfection agents themselves. Recently, there were developments of chemical conjugation of SPIOs onto cellular membrane. To this end, the surface of SPIOs was coated with heparin polysaccharide and chemically conjugated with collagen matrix layer of cell surface by using linker polymer, which was stably maintained in vivo. This new remedy can overcome the limitations of cell labelling via endocytosis. Collectively, these strategies could be applied for noninvasive imaging of MRI after cell transplantation in vivo.